Publications by authors named "H Mullerova"
Background: Patients with chronic obstructive pulmonary disease (COPD) have elevated cardiopulmonary and mortality risk, particularly following exacerbations. While single inhaler triple therapies (SITTs), such as budesonide/glycopyrrolate/formoterol fumarate (BGF), reduce cardiopulmonary risk versus dual bronchodilator therapy, there is limited evidence comparing outcomes with SITTs versus multiple inhaler triple therapies (MITTs).
Methods: SKOPOS-MAZI was a retrospective comparative effectiveness study in patients with COPD aged ≥40 years using US administrative claims data from Optum's deidentified Clinformatics® Data Mart Database.
Article Synopsis
- Oral corticosteroids (OCS) are commonly used to manage exacerbations of chronic obstructive pulmonary disease (COPD) but can lead to negative health outcomes that increase healthcare costs and resource use.
- A study analyzed data from the UK Clinical Practice Research Datalink to compare healthcare attendance and costs between COPD patients who used OCS and those who didn’t, focusing on hospital visits and costs.
- Results showed that patients who used OCS had significantly higher healthcare attendance and costs, with the increases correlating positively with the cumulative OCS dose, particularly for primary care consultations and emergency visits.
Article Synopsis
- In Japan, there are different inhaler combinations for treating chronic obstructive pulmonary disease (COPD), including single-inhaler and multiple-inhaler triple therapies, but there is limited information about how patients are actually treated in real-life scenarios.
- This study reviewed data from COPD patients in Japan from May 2018 to December 2021, categorizing them into four groups based on the triple therapy they started, including early adopters of a specific therapy and users of other available combinations.
- The findings revealed that a high percentage of patients had asthma as a comorbidity, and around 14% to 18% experienced moderate to severe exacerbations in the year before starting treatment, indicating significant healthcare resource utilization
Temporal Dynamics of Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease During Stable Disease and Exacerbations: Review of the Mechanisms and Implications.
Int J Chron Obstruct Pulmon Dis
October 2024
Introduction: Exacerbations of chronic obstructive pulmonary disease (COPD) are risk factors for severe cardiovascular (CV) events, with the risk remaining significantly elevated long after the symptomatic phase of the exacerbation. The pathophysiology underpinning the relationship between acute events of both COPD and CV diseases has been understudied. Our objectives were to review the mechanisms by which COPD exacerbations increase the risk of CV events and understand the temporality of this risk.
View Article and Find Full Text PDFArticle Synopsis
- Respiratory infections are a major global health issue, but the genetic factors influencing them are not well understood, leading to this study that aimed to investigate genetic determinants through genome-wide association studies (GWAS).
- The research analyzed data from 19,459 patients with respiratory infections and 101,438 controls in Stage 1, discovering 56 significant genetic signals, including one strong signal related to a gene important for immune response, but the follow-up Stage 2 study did not replicate these findings.
- Possible reasons for the lack of replication include variations in how the studies were conducted and differences in patient populations, but the research suggests a novel gene may be linked to susceptibility to respiratory infections, warranting further investigation.